DR. XIAOQIN LIU (Orcid ID : 0000-0003-4519-1536)

Article type : Letter to the Editor

Maternal pregestational or gestational diabetes and childhood wheezing: A population-based cohort study

To the editor

Early-life exposures that modify intrauterine environment may influence the development of wheezing and asthma in children. Diabetes may be one of these compromising factors, possibly through mechanisms related to alterations in fetal allergen sensitization and lung maturation disruption (1, 2). Previous studies on diabetes and offspring wheezing/asthma have revealed contradicting findings (3, 4). Until now, no studies have examined whether the association between maternal diabetes and childhood wheezing/asthma varies by both types of diabetes and wheezing/asthma phenotypes.

Methods

We conducted a register-based cohort study, utilizing data from all Danish residents. We identified 569,649 liveborn singletons during 1996–2004 from the Danish Medical Birth Registry. We excluded 3,954 children with missing or gestational age < 22 weeks or > 45 weeks, 18,244 children who emigrated and 2,774 children who died before their 6th birthday.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/all.13551](https://doi.org/10.1111/all.13551)

This article is protected by copyright. All rights reserved

We retrieved information on diabetes diagnoses from the Danish National Diabetes Register, which contains information on patients with diabetes treated in either primary or hospital care in Denmark. We additionally identified mothers with gestational diabetes (ICD-10 code O24.4) in the Danish National Patient Register (DNPR). Type of diabetes was categorized as pregestational or gestational diabetes according to the timing of first treatment. We further classified pregestational diabetes into type 1 or type 2 diabetes (Supplemental Figure S1):

- 1) According to the DNPR diagnosis if the mother had one type of diabetes diagnosis recorded.
- 2) For those first diagnosed after 1995 and with no record in the DNPR, or those with both type 1 and type 2 diabetes records: according to first-time antidiabetic prescription, insulin for type 1 diabetes, and oral antidiabetics for type 2 diabetes.
- 3) For those remaining, with undetermined diabetes type, we used age at first-time diabetes treatment < 30 and ≥ 30 years as the cut-off for type 1 and type 2 diabetes respectively (5).

Our outcomes of interest were childhood wheezing phenotypes determined by wheezing treatment (i.e., hospital treatment for wheezing or anti-asthmatic drug treatment) during 0–3 years of age and 4–6 years similar to a previous study from our group (6). Information on hospital treatment was based on ICD-10 codes J45 and J46 from the DNPR and anti-asthmatic drug treatment based on Anatomical Therapeutical Chemical classification codes (Supplemental Table S1) from the Danish National Prescription Registry. We defined wheezing treatment at age 0–3 years as at least two anti-asthmatic drug prescriptions within one year period or at least one hospital treatment for wheezing during 0–3 years. Wheezing treatment at age 4–6 years was similarly defined. We categorized children into four mutually exclusive groups:

- 1) *No wheezing*: no wheezing treatment;
- 2) *Early-onset transient wheezing*: wheezing treatment during 0–3 years of age only;
- 3) *Early-onset persistent wheezing*: wheezing treatment both during 0–3 years and 4–6 years of age;
- 4) *Late-onset wheezing*: wheezing treatment during 4–6 years of age only.

Note that for the present study we termed our outcome of interest as wheezing and not asthma, acknowledging the challenges in diagnosing symptoms related to narrowing of airways and breathing problems in young children.

Statistical analyses were performed with Stata 15.0. Since odds ratios tend to overestimate associations when outcomes are common, we used log-binomial regression to analyze the data with robust standard errors, as some individuals are siblings. The magnitude of the associations of each type of maternal diabetes with each wheezing phenotype was presented as prevalence ratios (PRs). The following confounders were included: maternal age, parity, smoking during pregnancy, asthma, thyroid disorders before childbirth, employment status at conception, and child calendar year at birth. Values for covariates were missing for 3.8% of children, and we applied 20 imputations to impute missing values.

Results

Of 544,677 children, 3,146 (0.6%) were born to mothers with pregestational type 1 diabetes, 841 (0.2%) with pregestational type 2 diabetes, and 7,913 (1.5%) with gestational diabetes. Table 1 shows the characteristics of the study subjects.

Gestational diabetes was associated with small increased risk of early-onset transient wheezing (adjusted PR=1.08, 95% CI: 1.00–1.17) and early-onset persistent wheezing (PR=1.15, 95% CI: 1.05–1.26) in offspring, compared to mothers without diabetes. Pregestational type 1 diabetes was associated with a clearly increased risk of early-onset wheezing in offspring: PRs were 1.30 (95% CI: 1.17–1.45) for early-onset transient wheezing and 1.25 (95% CI: 1.08–1.44) for early-onset persistent wheezing. Neither gestational nor type 1 diabetes was associated with offspring late-onset wheezing. We found no evidence that pregestational type 2 diabetes was associated with any wheezing phenotypes in children (Figure 1).

Altogether 9.4% of the 11,900 children were born to mothers with diabetes complications (ketoacidosis or diabetic coma, nephropathy, retinopathy, neuropathy, or vasculopathy/angiopathy) before childbirth; these children had higher risk of early-onset transient (PR=1.22, 95% CI: 0.97–1.52) and persistent wheezing (PR=1.21, 95% CI: 0.91–1.61) than children of mothers without diabetes (Supplemental Table S2).

The results were similar when we repeated our analyses among those with one recorded type of diabetes (Supplemental Table S3). The associations of offspring wheezing phenotypes with type 1

diabetes remained unchanged after further adjustment for maternal prepregnancy body mass index, while the associations with gestational diabetes were no longer statistically significant (Supplemental Figure S2).

Discussion

Pregestational type 1 and gestational diabetes were associated with small increased risk of early-onset transient wheezing and persistent wheezing, but not late-onset wheezing in offspring. Pregestational type 2 diabetes was not associated with any childhood wheezing phenotypes.

Currently, the underlying mechanisms behind the association between maternal diabetes and childhood wheezing are unknown. In the presence of diabetes, the fetus is exposed to abnormally high glucose levels, whereas the fetal pancreas exhibits limited responses to acute changes in cord blood glucose (7). This may result in fetal hyperinsulinemia and consequently hypoxia (2), leading to lung maturation disruption (8). If this is true, we also would expect to see an impact of pregestational type 2 diabetes, which was not observed. It is possible that mothers with type 2 diabetes have better glycemic control than mothers with type 1 or gestational diabetes (9). Our finding of particularly increased risk in mothers with diabetes complications may implicate poor glycemic control. Additionally, type 1 diabetes is an autoimmune disease, and autoantibodies that cross the placenta may act directly on fetal lung development (10). Further research and replications are needed to validate our findings and determine the likely complex mechanisms underlying diabetes and risk of offspring wheezing.

References

1. Kumar R, Ouyang F, Story RE, Pongracic JA, Hong X, Wang G, et al. Gestational diabetes, atopic dermatitis, and allergen sensitization in early childhood. *J Allergy Clin Immunol* 2009;**124**(5):1031-1038.e1031-1034.
2. Taricco E, Radaelli T, Rossi G, Nobile de Santis MS, Bulfamante GP, Avagliano L, et al. Effects of gestational diabetes on fetal oxygen and glucose levels in vivo. *Bjog* 2009;**116**(13):1729-1735.
3. Azad MB, Becker AB, Kozyrskyj AL. Association of maternal diabetes and child asthma. *Pediatr Pulmonol* 2013;**48**(6):545-552.

- 113 4. Zugna D, Galassi C, Annesi-Maesano I, Baiz N, Barros H, Basterrechea M, et al. Maternal
114 complications in pregnancy and wheezing in early childhood: a pooled analysis of 14 birth cohorts.
115 *Int J Epidemiol* 2015;**44**(1):199-208.
- 116 5. Feltbower RG, McKinney PA, Campbell FM, Stephenson CR, Bodansky HJ. Type 2 and other
117 forms of diabetes in 0-30 year olds: a hospital based study in Leeds, UK. *Arch Dis Child*
118 2003;**88**(8):676-679.
- 119 6. Liu X, Agerbo E, Schlunssen V, Wright RJ, Li J, Munk-Olsen T. Maternal asthma severity and
120 control during pregnancy and risk of offspring asthma. *J Allergy Clin Immunol* 2017;**141**(3):886-
121 892.
- 122 7. Fowden AL, Hill DJ. Intra-uterine programming of the endocrine pancreas. *Br Med Bull*
123 2001;**60**:123-142.
- 124 8. Haworth SG, Hislop AA. Lung development-the effects of chronic hypoxia. *Semin Neonatol*
125 2003;**8**(1):1-8.
- 126 9. D. POD. Maternal diabetes and the consequences for her offspring. *Journal of development*
127 *disabilities* 2007;**13**:101-134.
- 128 10. Rottem M, Gershwin ME, Shoenfeld Y. Allergic disease and autoimmune effectors pathways.
129 *Dev Immunol* 2002;**9**(3):161-167.
- 130 Xiaoqin Liu^{1,*}, Esben Agerbo^{1,2,3}, Jiong Li^{4,5}, Shyamali C. Dharmage⁶, Reimar W. Thomsen⁴, Jørn
131 Olsen^{4,7}, Trine Munk-Olsen¹
- 132 ¹ The National Center for Register-based Research, Aarhus University, Aarhus, Denmark;
133 ² CIRRAU-Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark;
134 ³ Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark;
135 ⁴ Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark;
136 ⁵ Ministry of Education - Shanghai Key Laboratory of Children's Environmental Health,
137 Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, China;
138 ⁶ Allergy and Lung Health Unit, Melbourne School of Population and Global Health, University of
139 Melbourne, Australia;
140 ⁷ Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles,
141 California, USA.

142 * **Correspondence:** Xiaoqin Liu, the National Center for Register-based Research, Aarhus University,
143 Fuglesangs Allé 26, 8210 Aarhus V, Denmark. Phone: +45 8716 6268. Fax: +45 8716 4601. E-mail:
144 lxq@econ.au.dk

145 **Funding:** This study is funded by an Independent Postdoc Grant to Liu X. from the Danish Council for
146 Independent Research (Project No. DFF-5053-00156B). Agerbo E. and Munk-Olsen T. are supported
147 by iPSYCH, the Lundbeck Foundation Initiative for Integrative Psychiatric Research (R155-2014-
148 1724). Agerbo E. is also supported by Niels Bohr Professorship Grant from the Danish National
149 Research Foundation and the Stanley Medical Research Institute. Li J. is supported by National Natural
150 Science Foundation of China (81530086), the Nordic Cancer Union (176673, 186200), the Danish
151 Council for Independent Research (DFF-6110-00019B), Karen Elise Jensens Fond (2016), and the
152 PROCRIN project (financed by the Novo Nordisk Foundation and the Lundbeck Foundation). The
153 funders had no roles in study design and conduct of the study; collection, management, analysis, and
154 interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the
155 manuscript for publication.

156 **Conflicts of interest:** None.

157 **Author contributions:** X.L. designed the study, researched data, and wrote the manuscript. X.L., E.A.,
158 J.L., S.C.D., R.T., J.O., and T.M. reviewed/edited the manuscript and contributed to the discussion.
159 X.L. is the guarantor of this work, as such, had full access to all the data in the study and takes
160 responsibility for the integrity of the data and the accuracy of the data analysis. All the authors have
161 read and approved the final version of the manuscript.

162 **Table 1.** Characteristics of study population

Characteristics	Mothers without diabetes (n=532,777)	Mothers with diabetes		
		Pregestational Type 1 diabetes (n=3,146)	Pregestational Type 2 diabetes (n=841)	Gestational diabetes (n=7,913)
Maternal age at delivery (years)				
<25	80,456 (15.1)	343 (10.9)	23 (2.7)	795 (10.1)
25–29	194,368 (36.5)	1,205 (38.3)	66 (7.8)	2,306 (29.1)
30–34	180,595 (33.9)	1,210 (38.5)	291 (34.6)	2,779 (35.1)
≥35	77,358 (14.5)	388 (12.3)	461 (54.8)	2,033 (25.7)

Parity				
1	229,948 (43.2)	872 (27.7)	112 (13.3)	3,000 (37.9)
≥2	302,829 (56.8)	2,274 (72.3)	729 (86.7)	4,913 (62.1)
Maternal smoking during pregnancy				
Yes	115,440 (21.7)	703 (22.3)	161 (19.1)	1,643 (20.8)
No	397,663 (74.6)	2,201 (70.0)	628 (74.7)	5,835 (73.7)
Missing	19,674 (3.7)	242 (7.7)	52 (6.2)	435 (5.5)
Maternal employment status at conception				
Unskilled workers or not in labor market	191,501 (35.9)	1,275 (40.5)	410 (48.8)	3,280 (41.5)
Skilled workers and white-collar workers	207,950 (39.0)	1,272 (40.4)	257 (30.6)	3,065 (38.7)
Top-level status	133,075 (25.0)	597 (19.0)	174 (20.7)	1,565 (19.8)
Missing	251 (<0.1)	<5	0	<5
Calendar year of birth				
1996–1998	181,684 (34.1)	864 (27.5)	176 (20.9)	2,476 (31.3)
1999–2001	178,377 (33.5)	1,102 (35.0)	304 (36.2)	2,461 (31.1)
2002–2004	172,716 (32.4)	1,180 (37.5)	361 (42.9)	2,976 (37.6)
Maternal diabetes complications before childbirth	-	1,003 (31.9)	85 (10.1)	36 (0.5)
Maternal asthma before childbirth	59,809 (11.2)	482 (15.3)	135 (16.1)	1,178 (14.9)
Maternal thyroid disorders before childbirth	7,133 (1.3)	145 (4.6)	40 (4.8)	172 (2.2)
Preterm birth	24,614 (4.6)	739 (23.5)	106 (12.6)	608 (7.7)
Fetal growth *				
Small for gestational age	52,202 (9.8)	136 (4.3)	46 (5.5)	557 (7.0)
Appropriate for gestational age	428,903 (80.5)	1,886 (60.0)	567 (67.4)	5,664 (71.6)
Large for gestational age	51,672 (9.7)	1,124 (35.7)	228 (27.1)	1,692 (21.4)

Figures are numbers (%). * Small for gestational age is defined as a birth weight below the 10th percentile of birth weight by the gestational age and sex, and large for gestational age as above the 90th percentile. The p-values for the comparison of differences among the four diabetes exposure categories were all less than 0.001, using chi-square tests.

166 **Figure 1.** Prevalence ratios of early-onset transient, early-onset persistent, and late-onset wheezing
167 according to type of maternal diabetes diagnosis (N=544,677)

168
169 Abbreviations: PR, prevalence ratio; CI, confidence interval.
170 *Adjusted for maternal age at childbirth (<25, 25–29, 30–34, and ≥35 years), maternal asthma (yes/no), maternal smoking
171 during pregnancy (yes/no), maternal parity at the index pregnancy (1st, or 2nd and above), maternal thyroid disorders before
172 childbirth (ICD-8 codes 240–246 and ICD-10 codes E00–E07; yes/no), maternal employment status at conception
173 (unskilled workers or not in labor market, skilled workers and white-collar workers, and top-level status), and calendar year
174 at birth (1996–1998, 1999–2001, and 2002–2004).

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Liu, X;Agerbo, E;Li, J;Dharmage, SC;Thomsen, RW;Olsen, J;Munk-Olsen, T

Title:

Maternal pregestational or gestational diabetes and childhood wheezing: A population-based cohort study

Date:

2018-11-01

Citation:

Liu, X., Agerbo, E., Li, J., Dharmage, S. C., Thomsen, R. W., Olsen, J. & Munk-Olsen, T. (2018). Maternal pregestational or gestational diabetes and childhood wheezing: A population-based cohort study. *ALLERGY*, 73 (11), pp.2247-2250. <https://doi.org/10.1111/all.13551>.

Persistent Link:

<http://hdl.handle.net/11343/284204>